Sugi Predict

Sugi Predict / Compounds / SCHEMBL10399987

SCHEMBL10399987

SCHEMBL10399987

O=C1CCCN1Cc1ccc(Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.67
▸ HRH3 Q9Y5N1 1/20 0.61
▸ KCNH2 Q12809 1/20 0.59
▸ WDR91 A4D1P6 2/20 0.56
▸ ACACB O00763 1/20 0.55
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ GRIA2 P42262 1/20 0.51
▸ GAA P10253 1/20 0.50
▸ F10 P00742 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ ERCC1 P07992 1/20 0.47
▸ ERCC4 Q92889 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11200681 0.92 L3MBTL1 (0.76) L3MBTL1HRH3KCNH2WDR91ACACB
SCHEMBL19717008 0.85 L3MBTL1 (0.67) L3MBTL1HRH3KCNH2WDR91ACACB
SCHEMBL13853398 0.84 L3MBTL1 (0.65) L3MBTL1HRH3KCNH2WDR91ACACB
SCHEMBL3903106 0.84 L3MBTL1 (0.65) L3MBTL1HRH3KCNH2WDR91ACACB
SCHEMBL5578262 0.84 L3MBTL1 (0.65) L3MBTL1HRH3ACACBCYP1A2CYP2C9
SCHEMBL13215733 0.84 L3MBTL1 (0.65) L3MBTL1HRH3ACACBCYP1A2CYP2C9
SCHEMBL632892 0.84 L3MBTL1 (0.65) L3MBTL1HRH3KCNH2WDR91ACACB
SCHEMBL256037 0.84 L3MBTL1 (0.65) L3MBTL1HRH3KCNH2WDR91ACACB
SCHEMBL6824717 0.84 L3MBTL1 (0.65) L3MBTL1HRH3KCNH2WDR91ACACB
SCHEMBL9293223 0.84 L3MBTL1 (0.65) L3MBTL1HRH3KCNH2WDR91ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20190142813-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON INTERNATIONAL CORPORATION 2019-05-16 — — US disclosed
US-10251872-B2 Multisubstituted aromatic compounds as serine protease inhibitors VERSEON CORPORATION (US) 2019-04-09 — — US disclosed
CN-106061961-B Selective N R2B antagonist 百时美施贵宝公司 2018-12-18 — — CN disclosed
US-10058541-B2 Multisubstituted aromatic compounds as serine protease inhibitors VERSEON CORPORATION (US) 2018-08-28 — — US disclosed
US-20180064698-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON INTERNATIONAL CORPORATION 2018-03-08 — — US disclosed
US-20170258775-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON INTERNATIONAL CORPORATION 2017-09-14 — — US disclosed
US-9687479-B2 Multisubstituted aromatic compounds as serine protease inhibitors VERSEON CORPORATION (US) 2017-06-27 — — US disclosed
US-20170065570-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS VERSEON INTERNATIONAL CORPORATION 2017-03-09 — — US disclosed
US-9533970-B2 Multisubstituted aromatic compounds as serine protease inhibitors VERSEON CORPORATION (US) 2017-01-03 — — US disclosed
CN-1229343-C Novel compounds ASTRAZENECA AB (SE) 2005-11-30 — — CN disclosed
CN-1426393-A Novel compounds ASTRAZENECA AB (SE) 2003-06-25 — — CN disclosed
US-4977178-A Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1990-12-11 — — US disclosed
US-4879391-A 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents PFIZER INC. (US) 1989-11-07 — — US disclosed
US-4861880-A 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1989-08-29 — — US disclosed
US-4476307-A Heteroylidene indolone compounds PFIZER INC. (US) 1984-10-09 — — US disclosed
US-4189495-A TREATMENT OF NERVOUS AND PSYCHOSOMATIC DISORDERS SYNTHELABO (FR) 1980-02-19 — — US disclosed
US-4172143-A PSYCHOSOMATIC AND PSYCHOLOGICAL DISTURBANCES SYNTHELABO (FR) 1979-10-23 — — US disclosed
US-4158060-A PSYCHOLOGICAL DISORDERS SYNTHELABO (FR) 1979-06-12 — — US disclosed
US-4021567-A FOR PSYCHOSOMATIC AND PSYCHOTIC DISTURBANCES SYNTHELABO (FR) 1977-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142813-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS SPINT2, PRSS1, SERPINB1 L3MBTL1 1838/4885HRH3 612/4885KCNH2 1450/4885
US-20180064698-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS SPINT2, PRSS1, SERPINB1 L3MBTL1 1838/4885HRH3 612/4885KCNH2 1450/4885
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 L3MBTL1 2195/4885HRH3 3341/4885KCNH2 4772/4885
US-10251872-B2 Multisubstituted aromatic compounds as serine protease inhibitors SPINT2, PRSS1, SERPINB1 L3MBTL1 1838/4885HRH3 612/4885KCNH2 1450/4885
US-10058541-B2 Multisubstituted aromatic compounds as serine protease inhibitors SPINT2, PRSS1, SERPINB1 L3MBTL1 1838/4885HRH3 612/4885KCNH2 1450/4885
US-20170065570-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS SPINT2, PRSS1, SERPINB1 L3MBTL1 1838/4885HRH3 612/4885KCNH2 1450/4885
US-20170258775-A1 MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS SPINT2, PRSS1, SERPINB1 L3MBTL1 1838/4885HRH3 612/4885KCNH2 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.